Honz Pharmaceutical Co.Ltd(300086) : 2021 environmental, social and Governance (ESG) report www.honz.com com. cn. Honz Pharmaceutical Co.Ltd(300086)
Stock Code: Honz Pharmaceutical Co.Ltd(300086) catalogue
Contents
About this report 03
Into Kangzhi 04
1. Company Introduction 05
2. Company brand 05
3. Digital Kangzhi 06
4. Kangzhi honor (part) 07
5. Strategy and vision 08
6. Responsibility management 08
Environment – green production, low-carbon operation 09
1. Introduction to environmental management system ten
2. Description of pollution eleven
3. Use of resources and energy fifteen
4. Greenhouse gas emissions seventeen
5. Emergency treatment of environmental accidents eighteen
Society – product first, employee oriented twenty-one
1. Product safety and responsibility twenty-two
2. Privacy and information security twenty-four
3. Protection of employees’ rights and interests twenty-four
4. Supply chain management twenty-eight
5. Charity twenty-nine
Governance – compliance operation, system management thirty-two
1. Board structure thirty-three
2. Investor relations management thirty-five
3. Safeguarding shareholders’ rights and interests thirty-six
4. Protect the rights of shareholders to participate in the company’s decision-making thirty-seven
2022 responsibility commitment thirty-eight
About this report
About this report is compiled and released by 3 Ning Xia Yin Xing Energy Co.Ltd(000862) 021 environmental, social and Governance (ESG) report (hereinafter referred to as ” Honz Pharmaceutical Co.Ltd(300086) ,” Kangzhi “or” company “,” we “) to truly and objectively reflect the practice of Honz Pharmaceutical Co.Ltd(300086) 2021 in environmental, social and governance, and help shareholders, employees, government, customers, partners The public and other stakeholders have a better understanding of the operation of the enterprise and an in-depth perspective on the efforts and achievements of Honz Pharmaceutical Co.Ltd(300086) in the practice of sustainable development. Scope of report
This report covers the period from January 1, 2021 to December 31, 2021. Unless otherwise specified, the data and cases in the report are from Honz Pharmaceutical Co.Ltd(300086) and its branches (subsidiaries). Preparation standard
This report is prepared with reference to the guidelines on environmental, social responsibility and corporate governance information disclosure of listed companies and in combination with industry characteristics and Honz Pharmaceutical Co.Ltd(300086) actual situation. Reliability commitment
This report is reviewed and approved by the board of directors of the company. The board of directors and all directors of the company guarantee that this report does not contain any false records, misleading statements or major omissions, and bear individual and joint liabilities for the authenticity and accuracy of its contents. Release form this report is released in the form of online version. The online version can be found on the company’s official website (www.honz. Com. CN.) And cninfo (www.cn. Info. Com. CN.) Access and download.
The preparation process of this report has comprehensively considered the relevance, materiality and availability of various indicators. Due to various objective reasons, the report may be unsatisfactory. We will continue to improve and optimize it in future reports.
Enter Kangzhi
About honz
Honz Pharmaceutical Co.Ltd(300086) , a listed enterprise focusing on children’s health (stock abbreviation: Honz Pharmaceutical Co.Ltd(300086) , stock code: Honz Pharmaceutical Co.Ltd(300086) ). Its main business covers children’s medicine, maternal and infant health products, medical services and other fields. It is a national high-tech enterprise and took the lead in establishing an enterprise postdoctoral research workstation with children’s medicine as the main research direction. The company always adheres to the corporate purpose of “sincere and good medicine, blessing mankind”, actively practices the “children’s great health strategy” and “high-quality strategy”, and creatively creates a national brand of children’s great health industry.
Honz Pharmaceutical Co.Ltd(300086) has deeply cultivated the children’s drug market for many years and formed a perfect product line. It is one of the few pharmaceutical enterprises in China with a whole industrial chain of R & D, production and sales of children’s drugs. The company has a national layout, with five production bases in Hainan, Beijing, Hebei, Liaoning and Guangdong provinces and cities, and highly automated and intelligent production lines. The company has advanced R & D equipment and excellent R & D team.
In 2018, Honz Pharmaceutical Co.Ltd(300086) acquired Zhongshan love daily necessities Co., Ltd., and the business layout was extended to the maternal and infant health sector, with the territory of Kangzhi children’s health becoming more and more perfect. The company has successively established cooperation with many scientific research institutions and universities at home and abroad, and was invited to participate in the formulation of the standard of liquid detergent for infant and child clothing materials. It is a leading enterprise in the field of maternal and infant health in China.
At the beginning of 2020, covid-19 pneumonia spread all over the world. Honz Pharmaceutical Co.Ltd(300086) was ordered to take the initiative to produce emergency masks and other protective materials. It took only 8 days to build the first disposable medical mask production line in Hainan, and successfully obtained the EU quality management system certification of EN ISO 134852016. In September 2020, it became the manufacturer of anti epidemic mask materials of the United Nations Development Programme.
Honz Pharmaceutical Co.Ltd(300086) has always been enthusiastic about public welfare undertakings. Over the years, we have actively fulfilled the social responsibility of corporate citizens in the relief of many major disasters such as the tsunami in Indonesia and the Ya’an earthquake and in the educational support of children in poor mountainous areas. In 2011, Kangzhi and China children’s foundation jointly established the “Kangzhi red face fund”, which benefited tens of millions of children through various forms of public welfare actions such as red face library donation, children’s health care, loving home visits and material donations.
Honz Pharmaceutical Co.Ltd(300086) is committed to becoming the leader of China’s children’s great health industry, continuously cultivating and developing in the field of children’s great health, and has successively won the awards of “China’s top ten most growing pharmaceutical enterprises”, “Forbes China potential enterprises”, “top 500 Asian brands”, “top 100 China Meheco Group Co.Ltd(600056) industrial enterprises” and so on.
In the future, Honz Pharmaceutical Co.Ltd(300086) will rely on the historical opportunity that the construction of Hainan free trade port has become a national strategy, unswervingly develop children’s health industry, take “making children use good medicine” as its own responsibility, adhere to the development strategy of “specialization and innovation”, and strive to become a leading enterprise in the field of children’s health in China.
Company brand pharmaceutical sector
Honz Pharmaceutical Co.Ltd(300086) has a complete product group of children’s medicine, covering children’s anti cold, anti fever, cough, diarrhea, anti allergy, anti infection and other categories.
At present, the company’s drug brands include: Kangzhi ®、 Kang Zhisong ®、 Kang Zhitai ®、 Ruizhiqing ®、 Xiao ruizhiqing ®、 Dolelin ®、 Jin Lishuang ® Etc. medical apparatus and instruments
In response to the covid-19 pneumonia epidemic, the company vigorously developed the field of medical protection and launched happy face ® And other protective equipment brands, and new medical products are added
Production and marketing of protective clothing such as respirator, disinfectant, hand sanitizer gel and so on are the manufacturers of anti epidemic mask materials of the United Nations Development Programme. In 2021, Honz Pharmaceutical Co.Ltd(300086) in line with the concept of meeting customer needs, launched personalized anti epidemic mask customization service, and worked with Kobayashi comics, Pepsi Cola and other brands to produce “Kangzhi characteristic customized anti epidemic mask”, which was highly praised by the market. Maternal and infant health
Honz Pharmaceutical Co.Ltd(300086) its care company has long focused on the field of maternal and infant health, and is committed to providing professional skin care guidance and help for baby families. Owned by the company ® He Youmiao ® Two major brands of maternal and infant health care, and their products are exported to many countries and regions.
Digital Kangzhi
3 pharmaceutical sector
》
Strategic business medical services Maternal and infant health
28 years of experience in R & D, production and sales of children’s drugs
Top 500 Asian brands
Five major production bases in China
There are more than 100 kinds of pharmaceutical products and more than 200 single products for maternal and infant health
265 pharmaceutical sector has 5100500 Chinese patents and 5 foreign patents of the same family
42. The maternal and infant health sector has Chinese patents
Item 3 200 26
There are nearly 1000 agents and more than 40000 sales terminals in China
Main historical honors of Kangzhi honor 2007 excellent brand of China’s high-tech industry 2008 China new industrialization Contribution Award 2009 famous trademark of Hainan Province (Kangzhi) ®）
Famous trademark of Hainan Province (ruizhiqing) ®）
2010 National Torch Plan key high-tech enterprises 2011 Forbes China potential enterprises 2012 China children’s charity outstanding contribution award 2013 top 500 Asian brands 2014 China famous trademark (Kangzhi) ®）
“Reassuring drug Award” of the 9th People’s safe drug use survey
2015 best responsible Brand Award
China’s top 100 most influential pharmaceutical enterprises
2016 listed company with the most brand value 2017 China Women’s and children’s Charity Award
Star of transformation of scientific and technological achievements
2018 9th Hainan excellent enterprise 2019 listed company Social Responsibility Award 202010th Hainan excellent enterprise
The most promising listed company in the great health industry
National anti epidemic advanced private enterprise
Main honors in 2021 Honz Pharmaceutical Co.Ltd(300086) : 2021 top 100 enterprises in Hainan Province 2021 top 35 manufacturing enterprises in Hainan Province “specialized and special new enterprises” in Hainan Province in 2021 Covid-19 love unit award for prevention and control of pneumonia epidemic, anti epidemic Pioneer Award, Chinese enterprise ESG annual best case award, 2021 outstanding contribution to science and technology empowerment, enterprise biomedicine, the most growing listed company, 2021 capital operation “Star” company Honz Pharmaceutical Co.Ltd(300086) Zhike Juhong granule was selected as the “key R & D plan project of Hainan Province in 2021” Honz Pharmaceutical Co.Ltd(300086) children’s Dextromethorphan Hydrobromide membrane was selected into the “Haikou major science and technology project” love company: anti epidemic love Enterprise Award “love donation and good deeds to help others” honorary title “caring charity and boundless love” honorary title Kangda marketing: anti epidemic pioneer enterprise
strategy and vision
Honz Pharmaceutical Co.Ltd(300086) will firmly rely on the historical opportunity that the construction of Hainan free trade port has become a national strategy, unswervingly develop children’s health industry, take “making children use good medicine” as its own responsibility, adhere to the development strategy of “specialization and innovation”, and strive to become a leading enterprise in the field of children’s health in China.
Children’s great health strategy and strategic vision are committed to becoming China’s children
Leading enterprise in the field of boutique strategic health
Responsibility management
Honz Pharmaceutical Co.Ltd(300086) implement the sustainable development management to the daily operation level, improve the enterprise ESG management system, establish an ESG working group, and actively communicate with stakeholders on major issues related to the company’s environment, society and governance Honz Pharmaceutical Co.Ltd(300086) hope to bring far-reaching changes to human health and social sustainable development through their own efforts. ESG management
Adhering to the original intention of being responsible for society and environment, we establish ESG management objectives within the enterprise. As the highest responsible organization of ESG working group, the board of directors is responsible for approving ESG reports and supervising and managing ESG matters. The strategy committee is responsible for planning and studying the company’s medium and long-term strategy, making suggestions on the formulation of the company’s ESG objectives, and supervising and evaluating the implementation progress of the objectives. At the same time, the strategy committee needs to study the development trend of ESG, evaluate and make suggestions on the major decisions of the company in ESG. The company sets up an ESG working group, which is composed of personnel from the office of the board of directors, the securities department, the brand management department, the human resources department, the information technology department, the national production center and other ESG related departments, to be responsible for the preparation and release of ESG reports and report to the strategy committee.
Environmental green production, low carbon operation
According to the relevant guidelines of ESG, Honz Pharmaceutical Co.Ltd(300086) each production base has established a sound enterprise environment, safety production and quality management system in each production base based on the environmental safety policy of “saving energy and reducing consumption, preventing and controlling pollution, advocating green environmental protection; people-oriented, eliminating hidden dangers, paying attention to health and safety; abiding by laws and regulations, full participation, realizing prevention and control; continuous improvement, continuous improvement and improving management performance”. At the same time, the company insisted on strengthening safety education and training, prevention and control in the whole process, continuously improved and improved the level of environmental protection management, and achieved good management performance in safety production.
Introduction to environmental management system
IntroductionOfTheManagementSystemForEnvironment
